Sponsored by AbbVie Medical Affairs
Dr. John Cush RheumNow
Dr. John Cush RheumNow
Dr. John Cush RheumNow
Dr. John Cush RheumNow
Dr. John Cush RheumNow
Dr. John Cush RheumNow
Dr. John Cush RheumNow
RA: One JAK to Rule Them All? Dr. Brian Jaros reports on abstract 1362, presented at #ACR24. https://t.co/QChMyma3Y2 https://t.co/qq3BqpT2Gh
Dr. John Cush RheumNow
Dr. John Cush RheumNow
Dr. John Cush RheumNow
Dr. John Cush RheumNow
JAKi in inflammatory myositis? #ACR24 will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis disease… https://t.co/SnqvElwk0B https://t.co/A5mJbpmB5P
Dr. John Cush RheumNow
Where there’s smoke, there’s flare: how pollution fuels RA The World Health Organisation (WHO) has declared climate change to be the greatest threat to human health in the 21st century, likely to contribute to an additional 250,000 deaths annually between 2030 and 2050 (1, 2)… https://t.co/hmXPa492Qr https://t.co/BBClCplk8Z